Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 12

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 12
---
 foreign private issuer at such time as more than 50% of
our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of
our executive officers or directors are U.S. citizens or residents; (ii) more than 50% of our assets are located in the United States;
or (iii) our business is administered principally in the United States.

Both foreign private issuers and emerging growth
companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as
an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures
required of companies that are neither an emerging growth company nor a foreign private issuer.

<div align='center'>3</div>

THE OFFERING

| Common                                                                                                        
 shares currently issued and outstanding                                                                       |     | 5,134,786 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Common Shares offered by the selling shareholders                                                             |     | Up to an aggregate of 1,126,480 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Common                                                                                                        
 Shares to be issued and outstanding after this offering (assuming exercise of the January 2024 PIPE Warrants) |     | 6,261,266 common shares (assuming exercise of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 January 2024 PIPE Warrants)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Use of proceeds                                                                                               |     | We will not receive any proceeds from the sale of the common shares by the selling shareholder. All net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholder. However, we may receive the proceeds from the exercise of any January 2024 PIPE Warrants if the selling shareholders do not exercise the January 2024 PIPE Warrants on a cashless basis, if and when exercised. See the section of this prospectus titled “Use of Proceeds.”                     |
| Risk factors                                                                                                  |     | Investing in our securities involves a high degree of risk. You should read the “Risk Factors” section starting on page 5 of this prospectus and “Item 3. - Key Information – D. Risk Factors” in our annual report on Form 20-F for the year ended October 31, 2024, or the 2024 Annual Report, incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our